Beta Bionics (NASDAQ:BBNX) Now Covered by Robert W. Baird

Stock analysts at Robert W. Baird started coverage on shares of Beta Bionics (NASDAQ:BBNX) in a note issued to investors on Thursday,Briefing.com Automated Import reports. The brokerage set a “neutral” rating and a $20.00 price target on the stock. Robert W. Baird’s price objective points to a potential downside of 8.30% from the stock’s current price.

Beta Bionics Price Performance

Shares of BBNX opened at $21.81 on Thursday. Beta Bionics has a 52 week low of $21.35 and a 52 week high of $24.50.

Insider Buying and Selling

In related news, insider Mike Mensinger acquired 33,350 shares of the stock in a transaction dated Friday, January 31st. The stock was acquired at an average cost of $17.00 per share, with a total value of $566,950.00. Following the purchase, the insider now directly owns 59,019 shares of the company’s stock, valued at approximately $1,003,323. This trade represents a 129.92 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the stock in a transaction dated Friday, January 31st. The stock was bought at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the purchase, the insider now directly owns 3,901,599 shares in the company, valued at approximately $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.